The recommended starting dose of Empagliflozin (Jardiance) is 10 mg once daily.
In patients tolerating empagliflozin 10 mg once daily and requiring additional glycaemic control, the dose can be increased to 25 mg once daily. Empagliflozin (Jardiance) can be taken with or without food.
Patients with renal impairment: Empagliflozin (Jardiance) is contraindicated in patients with persistent eGFR < 45mL/min/1.73m2 (see Contraindications and Precautions). No dose adjustment is required for patients with eGFR ≥ 45mL/min/1.73 m2.
Patients with hepatic impairment: No dose adjustment is recommended for patients with hepatic impairment.
Elderly Patients: No dosage adjustment is recommended based on age. Therapeutic experience in patients aged 85 years and older is limited. Initiation of empagliflozin therapy in this population is not recommended (see Precautions).
Combination therapy: When Empagliflozin (Jardiance) is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. (see Side Effects and Interactions).
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
Paediatric population: Safety and effectiveness of Empagliflozin (Jardiance) in children under 18 years of age have not been established.